Published in Cancer Immunol Immunother on March 25, 2009
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β. J Leukoc Biol (2015) 1.43
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res (2013) 1.16
Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol (2010) 1.02
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. Oncotarget (2015) 0.80
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res (2016) 0.78
Systematic analysis of copy number variants of a large cohort of orofacial cleft patients identifies candidate genes for orofacial clefts. Hum Genet (2015) 0.77
Down regulation of genes involved in T cell polarity and motility during the induction of heart allograft tolerance by allochimeric MHC I. PLoS One (2009) 0.76
Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells. Oncotarget (2017) 0.75
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol (2006) 9.53
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A (2005) 5.96
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
Cytokine receptors and signal transduction. Annu Rev Immunol (1992) 3.27
Spred is a Sprouty-related suppressor of Ras signalling. Nature (2001) 2.87
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol (2005) 2.64
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol (2004) 2.24
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res (2008) 2.19
CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol (2004) 2.00
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 1.81
Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood (2003) 1.79
Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med (2003) 1.52
Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol (1996) 1.49
Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol (2005) 1.38
Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol (2001) 1.35
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol (2005) 1.35
Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling. Mol Cell Biol (2007) 1.34
Cutting edge: TGF-beta-induced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol (2008) 1.34
Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene (2006) 1.34
Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res (1994) 1.29
Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. J Biol Chem (2004) 1.28
Effective cancer therapy through immunomodulation. Annu Rev Med (2006) 1.26
Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes (2008) 1.25
T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immunol (2002) 1.23
Extracellular signal-regulated kinases in T cells. Anti-CD3 and 4 beta-phorbol 12-myristate 13-acetate-induced phosphorylation and activation. J Immunol (1992) 1.13
IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol (2005) 1.09
Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. J Exp Med (2005) 1.07
Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest (1999) 1.02
Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol (2008) 0.98
Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-beta: contrasting effects of anti-CD2 and anti-CD3. J Immunol (1998) 0.96
CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest (1998) 0.93
Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J Immunol (2000) 0.93
Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res (1999) 0.93
Membrane-associated TGF-beta1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J Immunol (2006) 0.91
Costimulatory strength influences the differential effects of transforming growth factor beta1 for the generation of CD8+ regulatory T cells. Mol Immunol (2008) 0.83
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest (2003) 3.01
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation (2005) 2.79
Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood (2003) 2.65
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 2.54
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol (2004) 2.47
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 2.44
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res (2008) 2.19
The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg (2005) 2.17
Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum (2009) 2.16
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest (2010) 1.98
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res (2002) 1.77
Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappaB. Hepatology (2004) 1.76
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One (2010) 1.66
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res (2007) 1.65
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood (2004) 1.62
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res (2003) 1.59
Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 1.50
Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. Eur J Cardiothorac Surg (2007) 1.50
Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol (2006) 1.50
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 1.49
The effects of chymase on matrix metalloproteinase-2 activation in neointimal hyperplasia after balloon injury in dogs. Hypertens Res (2007) 1.45
Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res (2003) 1.44
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol (2012) 1.44
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res (2009) 1.41
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res (2012) 1.38
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35
Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol (2003) 1.34
Modeling metastasis biology and therapy in real time in the mouse lung. J Clin Invest (2010) 1.32
Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One (2010) 1.31
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
Inhibition of TLR3 and TLR4 function and expression in human dendritic cells by helminth parasites. Blood (2008) 1.27
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol (2002) 1.24
Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res (2009) 1.24
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res (2006) 1.23
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res (2007) 1.22
Streptococcus suis in humans, Thailand. Emerg Infect Dis (2008) 1.21
Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat (2009) 1.20
Stage-specific proteomic expression patterns of the human filarial parasite Brugia malayi and its endosymbiont Wolbachia. Proc Natl Acad Sci U S A (2011) 1.20
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20
Brugia malayi microfilariae induce cell death in human dendritic cells, inhibit their ability to make IL-12 and IL-10, and reduce their capacity to activate CD4+ T cells. J Immunol (2003) 1.19
Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther (2006) 1.19
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J Immunol (2008) 1.16
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res (2004) 1.15
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res (2013) 1.15
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm (2004) 1.15
Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. J Mammary Gland Biol Neoplasia (2009) 1.15
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology (2007) 1.15
Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol (2007) 1.14
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res (2008) 1.14
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14
Priming of CD8+ and CD4+ T cells in experimental leishmaniasis is initiated by different dendritic cell subtypes. J Immunol (2009) 1.13
Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci (2006) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol (2005) 1.12
Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res (2009) 1.12
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res (2002) 1.10
Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res (2008) 1.10